August 30, 2012

CT joins $181M settlement with Janssen Pharmaceuticals

Atty. Gen. George Jepsen and state Department of Consumer Protection Commissioner William Rubenstein announced Thursday that Connecticut has joined a $181 million dollar settlement agreement with Janssen Pharmaceuticals, Inc., a subsidiary of Johnson and Johnson.

Thirty-three other states and the District of Columbia also are participating in the agreement, the largest multi-state consumer protection settlement with a pharmaceutical company. It follows an extensive, four-year investigation and stems from allegations that Janssen improperly marketed the antipsychotic drugs Risperdal, Risperdal Consta, Risperdal M-Tab and Invega.

Connecticut's share of the settlement is $3,539,549. Approximately $3.1 million will be paid into the General Fund; the remainder will be paid into the OAG and DCP consumer funds and the DCP's prescription-drug monitoring program.

The complaint alleges that Janssen promoted Risperdal for off-label use to treat Alzheimer's disease, dementia, depression, and anxiety, even though the U.S. Food and Drug Administration had not approved the drug for these purposes, nor had Janssen shown that Risperdal was safe and effective in treatment of these conditions.

Free E-Newsletters

Sign up now for our daily and weekly
e-newsletters! Click Here

Today's Poll Should CT mandate firms disclose more tax data?<>
Most Popular on Facebook
Copyright 2017 New England Business Media